Fifty (50) women were treated in the XPAND II study and implanted with the AeroForm device (89 devices). Study endpoint was successful completion of the second stage surgery and secondary endpoints were days to complete expansion and reconstruction, and patient/physician satisfaction. Inclusion criteria included age (18-70), BMI (<33) and tissue suitability for expansion. Following implantation, women self-administered 10cc doses of CO 2 up to three times daily. When adequate expansion was achieved, the expanders were then exchanged for standard breast implants.
CONCLUSION:
Results of the XPAND II continued access study build upon the previous results from the first randomized trial (XPAND) for twostage breast reconstruction using the AeroForm Tissue Expander System. These results validate that the AeroForm patient-controlled, needle-free CO 2 tissue expander is safe and effective for twostage breast reconstruction. following prosthetic breast reconstruction is often preceded by multiple complications, but there is a paucity of literature examining these sequences of events. Understanding the temporal relationships between associated complications can aid in managing patient expectations, timing surveillance, and planning interventions. We present a novel investigation of the "pedigree" of reconstructive failure, i.e. the patterns and temporal clustering of complications preceding it. Though previous authors have noted associations between complications like seroma, infection, and explantation, this is the first study to methodically explore the possible routes that lead to RF.
METHODS:
We examined our prospective intra-institutional database of prosthetic breast reconstructions from [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] . Patients lost to follow-up before six months were excluded. Missing variables were imputed over twenty iterations. Outcomes of interest were seroma, infection, flap necrosis, exposure, and RF defined as expander removal without replacement and/ or conversion to autologous reconstruction. We mapped a complete pedigree of all complication sequences leading to RF, and analyzed the timing and interdependence of the sequential events using risk ratios, multivariate regression, and Cox regression.
RESULTS:
The cohort comprised 1,867 breasts (1,225 patients). Median follow-up was 16.6 months. Complication rates and their median times-to-detection were: flap necrosis (8.7%, 21.5 days), seroma (3.1%, 27 days), infection (4.7%, 39 days), exposure (4.1%, 52 days), and RF (9.3%, 171 days).
Of the 373 breasts encountering some postoperative complication, 35.4% experienced more than one. Seroma increased the risk of subsequent infection (RR=6.52, p<0.001) and necrosis (RR=1.97, p<0.001). Necrosis increased the risk of subsequent exposure (RR=3.56, p<0.001). All complications increased risk of RF, particularly infection and exposure (RR=6.69 and RR=7.45 respectively, p<0.001). These findings remained significant after multivariate risk-adjustment.
The pedigree demonstrated three common, multistep routes to RF: seroma, infection, RF; necrosis, infection, RF; and necrosis, exposure, RF. There was a stereotyped 14-to-21-day interval between first and second events in these sequences. If a patient encountered the first two events in one of these sequences, the chance of subsequent RF was 60-70%.
CONCLUSION:
Flap necrosis and seroma are niduses for subsequent complications, which tend to occur within a three-week window after these initial events. When a subsequent complication does occur, risk of RF can exceed 60%. Understanding the pedigree of RF may help the surgeon anticipate, surveil for, and manage complications. 
Tissue Expander Failure in Breast Reconstruction

METHODS:
After IRB approval, a retrospective review was performed of breast reconstruction patients who underwent early tissue expander removal from January 2009 to November 2015. Data was collected from medical records including the reason for early tissue expander removal. The surgical outcome was described as continuing or abandoning breast reconstruction after tissue expander removal and type of breast reconstruction in patients who proceeded. Wilcoxon rank sum test, Chi-squared test, and multivariable logistic regression were used to identify predictors of continuing breast reconstruction after early tissue expander removal.
RESULTS:
A total of 137 patients were included. Mean age was 53 years (range: 26-74 years).
Reasons for premature tissue expander removal were infection (51%), patient preference (18%), exposure (8%), oncologic reasons (6%), wound issues (5%), pain (4%), and other (7%). Fortythree percent of patients (95% confidence interval: 34-52%) continued with breast reconstruction. In univariate analysis, factors associated with continuing breast reconstruction included bilateral reconstruction (p=0.009), shorter time with tissue expander (p=0.003), presence of a contralateral tissue expander (p<0.001), younger age (p<0.001), and infection causing expander removal (p<0.001). Of these, infection causing expander removal (p=0.038), younger age (p=0.024), and shorter time with tissue expander (p=0.005) were still significant, independent predictors of continuing reconstruction with multivariable analysis. Successful final reconstruction was achieved with autologous reconstruction in 26 patients (48%), implants in 20 patients (37%), and combination of both in 4 patients (7%). Four patients (7%) failed final reconstruction.
CONCLUSION:
Tissue expanders are a key feature of breast reconstruction. To our knowledge, this is the most comprehensive description of tissue expander failure long-term outcomes to date. Most early tissue expander removals are due to infection and a considerable portion of patients abandon reconstruction. New factors have been identified which may predict patients likely to continue breast reconstruction after early tissue expander removal. Both implantbased and autologous reconstruction may be utilized for successful final reconstruction in these patients.
